Publications

by | February 27, 2012 | Uncategorized

Pharmacovigilance: Transitional arrangements published & EMA consultation on good pharmacovigilance practice

The European Commission has published transitional arrangements for the new pharmacovigilance legislation that will come into force in July 2012. This coincides with a public consultation by the European Medicines Agency on the first modules on good pharmacovigilance practice (GVP). Deadline: 18 April 2012.

Transitional arrangements

Of particular interest to marketing-authorisation applicants and holders, the transitional arrangements for pharmacovigilance provide answers legal and practical questions on a range of topics including renewal of applications, pharmacovigilance system master files and risk management plans.

New pharmacovigilance legislation (Regulation 1235/2010 and Directive 2010/84/EU) was adopted by the European Parliament and European Council in December 2010. The European Medicines Agency (EMA) is responsible for implementing much of it and is developing a framework for compliance and delivery of key requirements.

Consultation on Good Pharmacovigilance Practice

To this purpose, the European Medicines Agency EMA has opened a public consultation on the first seven modules on good pharmacovigilance practices (GVP) until 18 April 2012. The release of these modules is a key deliverable of the pharmacovigilance legislation.

Each of the modules covers a major process in the safety monitoring of medicines. These are:

– Module I: Pharmacovigilance systems and their quality systems;
– Module II: Pharmacovigilance systems master files;
– Module V: Risk management systems;
– Module VI: Management and reporting of adverse reactions to medicinal products;
– Module VII: Periodic safety update reports;
– Module VIII: Post-authorisation safety studies; and
– Module IX: Signal management.

GVP is a set of measures drawn up to facilitate the performance of pharmacovigilance in the EU. They apply to marketing-authorisation holders, the EMA and medicines regulatory authorities in Member States and aim to improve safety for patients by strengthening pharmacovigilance across the EU. They cover medicines authorised centrally via the Agency and those authorised at national level. Hence each module was developed by a team consisting of experts from the Agency and from the Member States.

EMA is seeking comments on the practical implementation of the legislation as outlined in these modules, intended to be finalised by July after comments from stakeholders have been taken into account.

The remaining nine draft modules making up the entire GVP package are under development and will be released for consultation later in the year.

EPHA briefing on Pharmacovigilance Directive
—–

EPHA related articles

– [->art4782]
– [->art4665]
– [->art4838]
– [->art4372]
– [->art3920]
– [->art4967]
– [->art4910]
– [->art4712]
– [->art3735]

Get the EPHA Newsletter

The best of our activities, right in your inbox!